Vimarsana
Biggest News Aggregation in the World

Occupational Functioning Assessment Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Occupational Functioning Assessment Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Occupational Functioning Assessment Scale Today - Breaking & Trending Today

Clozapine: Once-Daily or Divided Dosing? - Vimarsana News

Clozapine: Once-Daily or Divided Dosing?

Compared with divided dosing, patients with once-daily dosing had shorter illness duration and better clinical outcomes.

Once Daily Versus Divided Dosing Regimens of Clozapine - Vimarsana News

Once Daily Versus Divided Dosing Regimens of Clozapine

To divide or not to divide? Researchers compared clinical features, side effects, and blood levels between once daily versus divided clozapine dosing regimens.

Investigating the Prevalence of Sleep Disorders in Patients With First-Episode Psychosis - Vimarsana News

Investigating the Prevalence of Sleep Disorders in Patients With First-Episode Psychosis

What is the nature of the relationship between psychosis and sleep disorders?

Amotivation and anhedonia play a crucial role in determining the social functioning of schizophrenia patients - Vimarsana News

Amotivation and anhedonia play a crucial role in determining the social functioning of schizophrenia patients

Dr. Raymond Chan's team from the Institute of Psychology of the Chinese Academy of Sciences and his collaborators have recently shown that amotivation and anhedonia, rather than expressive dysfunction, play a crucial role in determining the social functioning of schizophrenia patients.

Cognitive Biotype: A Novel Depression Subcategory Defying Conventional Treatments Identified - Vimarsana News

Cognitive Biotype: A Novel Depression Subcategory Defying Conventional Treatments Identified

Researchers discovered a new depression subtype, the 'cognitive biotype,' affecting 27% of patients who respond poorly to typically prescribed antidepressants.